Analyst Ratings for CARISMA Therapeutics
Portfolio Pulse from Benzinga Insights
CARISMA Therapeutics (NASDAQ:CARM) has received positive analyst ratings in the last quarter, with 3 bullish and 2 somewhat bullish ratings. The average price target is $10.6, indicating an upside from the current price of $5.93. This average has increased by 6.0% from the previous target of $10.00.
August 11, 2023 | 12:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Positive analyst ratings and an increased price target suggest potential upside for CARISMA Therapeutics.
Analyst ratings are a significant factor in influencing investor sentiment and stock price. The positive ratings and increased price target for CARISMA Therapeutics suggest that analysts are optimistic about the company's performance, which could lead to an increase in its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100